Back to results
US 7,166,439 B2Granted
Assay for anti-INGAP antibodies
AssigneeGMP Endotherapeutics, Inc.
InventorsAaron I. Vinik, David A. Taylor-Fishwick
Life of this patent
Estimating the term…
Abstract
A solid phase assay is used for detecting antibodies to INGAP104-118 peptide, a 15-amino acid peptide that is the biologically active portion of islet neogenesis associated protein (INGAP). The isotype of the antibodies to INGAP104-118 peptide can be determined. A kit can also be used in the detection of anti-INGAP104-118 antibodies. Endogenous autoantibodies or antibody production during therapeutic treatment of a mammal with INGAP104-118 can be monitored.
Claims9
A method for detecting antibodics to a Islet Neogenesis Associate Protein peptide (INGAP104-118 ) in a human test sample comprising:
- contacting the test sample with an Islet Neogenesis Associated Protein peptide of SEQ ID NO 1 bound to a solid support, wherein the contacting is under conditions sufficient for binding an anti-INGAP104-118 antibody to the INGAP104-118 peptide;
- contacting any bound test sample bound to the Islet Neogenesis Associated Protein peptide on the solid support with a detection antibody which specifically binds to antibody molecules of all antibody isotypes of the human;
- washing the solid support to remove any unbound antibody molecules to SEQ ID NO 1, and determining the detection antibody bound to the solid support, wherein detection antibody bound to the solid support indicates that the test sample contains antibodies to peptide of SEQ ID NO 1.
Dependencies are inferred from the claim text.